Silexion Therapeutics CORP DEF 14A proxy statements

Silexion Therapeutics Corp is holding an extraordinary general meeting to approve warrant exercisability and an increase in authorized share capital to maintain Nasdaq compliance.

Silexion Therapeutics Corp. is holding an extraordinary general meeting on April 28, 2026, to seek shareholder approval for proposals including an increase in authorized share capital, an amendment to its equity incentive plan, and a reverse stock split.

Silexion Therapeutics Corp. calls an extraordinary general meeting to approve a significant increase in authorized share capital and an expanded equity incentive plan to maintain Nasdaq listing and fund operations.

Silexion Therapeutics Corp. adjourned its extraordinary general meeting to August 19, 2025, to vote on increasing authorized share capital to meet Nasdaq listing requirements and enable future equity raises.

Silexion Therapeutics Corp. is seeking shareholder approval to significantly increase its authorized share capital to meet Nasdaq listing requirements and fund the development of its RNAi therapies.

A clinical-stage biotechnology company has adjourned its annual general meeting to July 14, 2025, and set a 1-for-15 reverse share split ratio to regain Nasdaq listing compliance and facilitate future capital raising.

Silexion Therapeutics Corp. has filed a supplement to its definitive proxy statement, updating the record date for its 2025 annual general meeting to June 24, 2025.

Silexion Therapeutics Corp. is convening its 2025 annual general meeting to seek shareholder approval for a reverse share split aimed at maintaining Nasdaq listing compliance and an increase in its equity incentive plan to better align employee and director interests.

Silexion Therapeutics has adjourned its extraordinary general meeting to November 19, 2024, and updated the proposed reverse share split ratio to 1-for-9 to regain Nasdaq compliance.

Silexion Therapeutics is asking shareholders to approve a reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement.